Effect of routine treatment with and without intravenous immunoglobulin (IVIG) on fertility induction in patients with repeated unexplained in vitro fertilization failure

Effect of routine treatment with and without intravenous immunoglobulin (IVIG) on Th17 and Th1:Th2 and CD56+16+ serum levels in patients with repeated unexplained in vitro fertilization failure: a randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N217

Enrollment

Registered

2018-04-21

Start date

2017-03-21

Completion date

Unknown

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility. Female infertility

Interventions

Intervention 1: Intervention group: Routine treatment plus intravenous immunoglobulin prepared from fresh plasma 400 mg/kg just single dose before embryo transfer. Intervention 2: Control group: Just

Eligibility

Sex/Gender

Female

Age

20 Years to 35 Years

Inclusion criteria

Inclusion criteria: Age of 20 to 35 years Repeated unexplained in vitro fertilization failure

Exclusion criteria

Exclusion criteria: Anatomical abnormalities of the uterus Endocrine disorder Genetic disorder Infectious diseases

Design outcomes

Primary

Measure	Time frame
Measuring Th17. Timepoint: Before intervention and two weeks after that. Method of measurement: Through laboratory test.;Measuring Th1:Th2. Timepoint: Before intervention and two weeks after that. Method of measurement: Through laboratory test.;Measuring CD56+16+. Timepoint: Before intervention and two weeks after that. Method of measurement: Through laboratory test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Tayebeh Artimani

Hamedan University of Medical Sciences

artimani@umsha.ac.ir+98 81 3828 3939

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026